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ABSTRACT 
 
  
The main line of my thesis projects is searching for biomarkers and evidence of 
optimal correlation with clinical and para-clinical outcome measurements in multiple 
sclerosis (MS): 
- investigating the biochemical biomarker in blood/plasma (cerebrosterol) and in 
cerebrospinal fluid (CSF) (oligoclonal bands (OCB)) and the correlation with MRI 
lesion load (paper 1 and paper IV);  
- investigating the genetic biomarker (CYP46A1) for susceptibility  and disability 
progression in MS (Paper III); 
-  comparison of the well-known positron emission tomography (PET) ligand and 
peripheral benzodiazepine receptor (PBR) antagonist, [11C]PK11195, and a new PET-
ligand [11C]vinpocetine (tissue receptor biomarker). Both ligands denote areas of 
active ongoing inflammation in MS (paper II). 
Paper I:  How levels of cerebrosterol – a brain specific cholesterol metabolite - 
correlate with inflammatory and neurodegenerative markers on brain MRI. 
 Paper II: PET ligand and PBR agonist, [11C]vinpocetine , facilitates cholesterol 
delivery to the mitochondrial membrane; a pilot study to investigate whether the new 
[11C]vinpocetine is a better marker of MS inflammatory lesion areas compared to the 
old PET -PBR marker [11C]PK11195. 
Paper III: A study of how a  single nucleotide polymorphism in the gene CYP46A1, 
coding for cholesterol hydroxylating enzyme 24S-hydroxylase, influences 
susceptibility and prognosis in MS singly and in synergism with another gene variant 
implicated in cholesterol turnover, APOE ε4. 
Paper IV: Investigation of a CSF inflammation biomarker –OCB, and carriership of 
specific HLA gene alleles and the correlation with MRI outcome measures: total T1 
and T2 lesion load, as well as T2 lesion load extension in MS specific compartments.    
 
 
The most important findings are:  
Paper I: results in this paper support the possibility that cerebrosterol in plasma is a 
potential marker of neurodegeneration in the relapsing remitting MS group.  
Paper II: PET ligand [11C]vinpocetine is a marker of activated glia in MS lesions and 
binds in different ways compared to [11C]PK11195.  
Paper III: CYP46A1 alone or in combination with APOE ε4 does not affect 
susceptibility for MS; men, as carriers of both the CYP46A1 SNP rs754203 –AA 
variant and APOE ε4 need walking assistance 17 years earlier compared with non-
carrier men. However, results are lacking statistical significance, due to small sample 
size.  
Paper IV: OCB in CSF, HLA-DRB1*15, and HLA-DRB1*04 affect neither T1 lesion 
load on brain MRI at MS specific localizations nor total T2 lesion load. This paper 
supports the possibility that infratentorial T2 lesion load is associated with OCB in 
CSF.  
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1 THESIS SUMMARY – MAIN SECTION 
  
1.1 MULTIPLE SCLEROSIS 
 
Multiple sclerosis (MS) is a complex autoimmune CNS disease that causes 
inflammation, demyelination, axonal degeneration and brain and spinal cord tissue 
atrophy. The disease affects individuals in their third decade of life; females affected 2-
3 times more often than males. One fourth of all patients never experience difficulties 
of daily living due to disease, but 15% of patients suffer disability in early disease 
stages (Compston and Coles 2002).   
Main subdivision of MS clinical courses: RRMS (relapsing-remitting, 80-90%) and 
PPMS ( primary progressive10-20%) ( reviewed in (Noseworthy, Lucchinetti et al. 
2000). The first decade after disease onset RRMS patients experience relapses, i.e. 
neurological disability that resolves with time and patients recover. With time, 10-15 
years later, patients do not recover completely after bout, or handicap accumulates 
without bouts; this stage is called secondary progressive form. Disability progression 
by some researchers is considered an age dependent process, independent of relapse 
history (Koch, Mostert et al. 2007).  
Patients might have a broad range of symptoms: motor disturbances, including walking 
disability, pain, coordination problems, sensory and balance disturbances as well 
bladder and bowel disturbances together with fatigue and cognitive impairment. 
Diagnosis. There is no specific test or biomarker that singly would indicate MS. MS 
diagnosis is made by combining relapse history, findings on magnetic resonance 
imaging (MRI) and exclusion of other differential diagnosis that would mimic either 
clinical or MRI phenotype. Currently used are McDonald’s diagnostic criteria which 
were modified in year 2010 (Polman, Reingold et al. 2011) from previous versions of 
year 2001 (McDonald, Compston et al. 2001) and year 2005 (Polman, Reingold et al. 
2005).  
According to the latest revision of McDonald’s criteria, RRMS diagnosis requires 
fulfillment of at least one of the following conditions:  
 -at least one MS relapse and one objective lesion on brain MRI and evidence of disease 
dissemination in time (DIT) and dissemination in space (DIS);   
-or at least one clinical attack, two MRI lesions and DIT;  
-or two attacks, one MRI lesion and DIS;  
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-or two attacks and two MRI lesions without additional requirements.  
PPMs is diagnosed when two major criteria are fulfilled:  
1. One year of disease progression (retrospectively or prospectively determined) 
2. and two of the three following criteria:  
A. Evidence for DIS in the brain based on one T2 weighted hyperintense lesions in at 
least one area characteristic for MS (periventricular, juxtacortical, or infratentorial) 
B. Evidence for DIS in the spinal cord based on two T2 weighted hyperintense 
lesions in the cord. 
C. Positive CSF (isoelectric focusing evidence of OCB and/or elevated IgG index) 
(Polman, Reingold et al. 2011).  
 
 
 
1.2 BIOMARKER  
 
A biomarker is a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenetic processes or pharmacological 
responses to a therapeutic intervention (Brex, Ciccarelli et al. 2002; Bielekova and 
Martin 2004). There are a few quite good biomarkers in MS (OCB or elevated IgG 
index are a diagnostic biomarker for inflammation in CNS; gray substance volume 
reduction is a marker of neurodegeneration), but we are lacking the surrogate 
biomarker to monitor treatment effects.  
 
 
1.2.1 Characteristics of a potential biomarker for use of 
clinical evaluation   
 
1.2.1.1 Biologically meaningful  
The biomarker must reflect a particular pathogenetic process. As example let us use 
neurofilament light chain or tau proteins as markers for axonal-neuronal damage or 
reduction of N-acetyl aspartate (NAA) marker for loss of axonal integrity. 
 
1.2.1.2 Clinically relevant 
Biomarker level variation needs to correlate to clinical outcome endpoints. In MS 
patients most common used endpoints are: EDSS (Expanded disability status scale), 
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MSSS (Multiple sclerosis severity scale), and MSFC (Multiple sclerosis functional 
composite), Ambulation index and SDMT (Symbol digit modalities test).  
 
1.2.1.3 Practical issues: easily obtainable, stable; cheap and quick sample analysis 
 
Currently known and future identified biomarkers will be more easily accepted and 
used clinically if they are tested in body fluids that are easily obtainable: CSF and tissue 
biopsy biomarkers have a sampling disadvantage compared to biomarkers in blood, 
tears and urine. Quick and cheap biomarker, easy sample analysis gives an advantage 
as well as stable, not easily degradable compound (biomarker).   
 
1.2.1.4 Correlates well with disease activity and accumulated disability  
 
Disease activity might be assessed by clinical or preclinical measures. As a clinical 
measure might be used either number of MS relapses per patient and year or the extent 
of progression in one of the disability scales per time unit.   
Paraclinical measures:  number of Gd-enhanced lesions; accumulation of disease 
burden measured as WMLL (white matter lesion load), number of accumulated T1 
hypointense lesions, increase in brain atrophy measures. However, disease activity does 
not always correlate with accumulated disability.    
  
1.2.1.5 Correlates with treatment effect 
 
If there is good correlation between the clinical endpoint and biomarker, treatment that 
predictably influences clinical endpoint, should influence levels of biomarker. 
  
 
1.2.2 Criteria to evaluate clinical usefulness of biomarker 
 
1.2.2.1 Sensitivity and specificity 
 
Adopted from (Motulsky 1995) 
 
Sensitivity is the fraction of all those with the disease who get a positive test result. 
Sensitivity might be calculated by formula: 
Sensitivity = True positives / (True positives+ False negatives) 
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Sensitivity measures how well the test identifies those with disease. If the test has high 
sensitivity, it will pick up nearly everyone with the disease.  
Specificity is the fraction of individuals without disease who will get a negative test 
result. It might be calculated by formula: 
Specificity = True negatives / (True Negatives + False positives) 
Specificity measures how well the test excludes those who do not have the disease. If a 
test has high specificity, it will not mistakenly give a positive result to many people 
without disease.  
 
1.2.2.2 Reliability 
 
A biomarker needs to be reliable with known biological variation depending on the 
time point of biomarker sampling; reproducible values of measurements despite 
different assays (inter-and intra-assay reproducibility); known frequency of false 
positive and false-negative results.  
  
 
1.2.2.3 Evaluation of biomarker in epidemiological studies of natural history 
cohorts 
Currently it is unethical to conduct such studies of natural history due to early treatment 
initiation soon after diagnosis for both clinical isolated syndrome (CIS) and MS 
patients. But on the other hand studies are essential to establish the statistical 
relationship between the biomarker and clinical outcome measurement in treatment-
naive patient.  
 
1.2.2.4 Evaluation of biomarker in large multicenter double-blinded therapeutic 
trials 
In such trials it is possible to evaluate the proportion of treatment effect for both clinical 
and biomarker endpoint and very valuable information could be collected for placebo 
group (untreated population).  
  
1.2.2.5 Evaluation of a biomarker in a meta-analysis   
In order to evaluate biomarker surrogacy it is important to evaluate a biomarker’s 
relationship to clinical endpoint in meta-analysis. Meta-analysis uses results from both 
small and large clinical trials of biomarker relationship to the major clinical outcome. 
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1.3 INFLAMMATION 
 
“Notae verae inflamationis sunt quattuor: rubor et tumor cum colore et dolore”  
                                                                                                             Cornelius Celsius 
 
 
These four signs of inflammation: redness, swelling with heat and pain, - definition of 
inflammation by Cornelius Celsius (about 25-30 BC – 50 AD). Rudolf Ludwig 
Virchow (1821-1902) added the fifth sign of inflammation: “functio laesa” (lat.), 
reduced function. That we learnt by heart at medical school.  
 
MS is considered an autoimmune inflammatory and neurodegenerative disease. Not all 
the classical signs of inflammation are present in MS-related neuroinflammation.  
Below are listed facts that that support the evidence of inflammation in MS 
pathogenesis: 
 
- Most important loci of disease susceptibility are related to immune function as 
published in the International Multiple sclerosis Genetic consortium  and Welcome  
Trust Case Control Consortium publication in Nature,  2011(Sawcer, Hellenthal et al. 
2011) .  GWAS, involving 9772 cases has replicated previous genes and loci of 
susceptibility: HLA-DRB1*15:01 has the strongest association with MS among all 
classical and SNP alleles; genes that are coding for cytokine pathway (IL7R, IL7, and 
CXCR5), co-stimulatory (CD37, CD40, CD80) and signal transduction (TYK2, 
STAT3) molecules of immunological relevance.  
 
- Genetic, cellular and tissue imaging studies give evidence for inflammation in lesions. 
MS lesions are characterized by infiltration of lymphocytes and antibody-producing 
plasma cells into the brain and spinal cord white matter. In areas of demyelination 
activated microglia, increased  amount of astrocytes (Lassmann, Bruck et al. 2001), 
complement and antibody deposition are present (Frohman, Racke et al. 2006).   
 
Mild meningeal inflammation consisting of B and T lymphocytes, plasma cells and 
macrophages are present.  
Subpial and intracortical gray matter lesions exist; subpial lesions are extensive and 
cover upp to 70% of the cortical area in some individuals (Kutzelnigg and Lassmann 
2005).  
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-Immunomodulatory treatment  reduces the inflammatory burden and reduces disability 
progression in the early stages of disease (Giacomini, Darlington et al. 2009).  
  
 
1.4 NEURODEGENERATION 
 
Both inflammation and neurodegeneration are closely related. It is important to 
emphasize that there is evidence that  neurodegeneration process occurs both early 
(Trapp and Nave 2008) and late in disease progression and in both gray (Calabrese and 
Gallo 2009)  and  white matter.  
In the early disease stage both in areas of demyelination as well as in areas of normal 
appearing white matter (NAWM) axonal damage and transection are present 
(Kutzelnigg, Lucchinetti et al. 2005).    
The extent of Gd-enhanced lesions correlates with subsequent brain atrophy; it means 
that high inflammatory burden has consequences of irreversible tissue damage, causing 
loss of brain parenchyma (Simon, Jacobs et al. 1999).  By MR spectroscopy, loss of 
NAA (biomarker metabolism in neurons) is visualized early in MS disease and in 
patients with very few lesions (De Stefano, Narayanan et al. 2001).  
 
In the late disease stage (approximately 10 years from disease start) 
immunomodulatory drugs are inefficient even if inflammatory burden has not 
completely disappeared. There is presence of chronic, active, slowly expanding lesions 
with demyelination, ongoing axonal damage and T-cell infiltration (Prineas, Kwon et 
al. 2001). According to a previous publication (Hochmeister, Grundtner et al. 2006) in 
late stages of disease inflammation may be trapped within the CNS and thus 
unreachable for immunomodulating treatment. Another concept of explanation for the 
inefficiency of immunomodulatory drugs in late stage of disease could be that 
neurodegeneration becomes independent from inflammation or inflammation seen in 
late stages of MS is consequence of neurodegeneration.  
Cortical lesions and cortical atrophy (volume reduction) contribute to cognitive deficits 
(Calabrese, Filippi et al. 2009).  
The pathological substrate of motor disability in MS, loss of corticospinal axons, 
correlates with clinical and pathological findings (Tallantyre, Bo et al. 2010). 
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2 MY PROJECTS AND PUBLICATIONS 
 
2.1 AIMS 
 
The overall aims in this thesis are to investigate how biochemical, genetic and tissue 
receptor biomarkers associate with the inflammation, neurodegeneration and correlate 
to clinical outcome in MS.  
 
2.1.1 Paper I 
 
To investigate and collect evidence as to whether variation in plasma concentration of 
cerebrosterol reflects ongoing inflammation or neurodegeneration in CNS expressed as 
volume of different brain MRI lesions.   
 
 
2.1.2 Paper II 
 
PET-pilot paper: validation of a new glia activation marker, ligand [11C]vinpocetine 
compared to the established ligand [11C]PK11195.  
 
 
2.1.3 Paper III 
 
Gene association paper: whether the CYP46A1 SNP (rs754203) that is a suggested 
genetic risk factor for late onset Alzheimer’s disease (AD) influences susceptibility for 
MS and/or disability progression both alone or in synergism with another 
neurodegeneration related and major  gene risk allele for sporadic AD—APOE ε4. 
 
 
2.1.4 Paper IV 
 
To investigate  the effect of OCB, HLA-DRB1*04, HLA DRB1*15 on total T2 and T1 
lesion load of  T1 hypointense  lesion load, and T2 lesion load in MS specific 
neuroanatomical compartments .   
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2.2 MARKERS OF INFLAMMATION AND NEURODEGENERATION 
 
2.2.1 T2 lesion load 
 
Definition:  T2 weighted lesions new, recurrent, newly enlarging, or persistently 
enlarging hyperintense lesions detected on serial T2 MRI scans (Paty 1988). 
 
 
 
Figure1. Axial fluid-attenuated inversion recovery-weighted brain MRI with lesion 
localization:  
1-Periventricular; 2- Deep white matter; 3-Subcortical; 4-Juxtacortical. 
 
 
2.2.2 Gadolinium-enhancing lesions 
 
Definition: Gadolinium-enhanced lesion areas of high signal intensity on T1-weighted 
images that appear after intravenous injection of gadolinium. Gadolinium-enhancing 
lesions indicate breakdown of the blood—brain barrier and inflammation in acute MS 
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lesions. They tend to persist for 2 to 6 weeks, leaving behind a T2 hyperintense lesion 
(Fazekas, Barkhof et al. 1999).  
 
 
2.2.3 T1 hypo-intense lesions  
 
 Definition: T1 - weighted hypointense lesions - black holes- qualitative term used to 
describe hypointense lesions in the white matter on T1-weighted images (short 
TR/short TE spin echo image). Acute black holes represent areas of edema related to 
acute inflammation, whereas chronic black holes indicate persistent tissue destruction 
with expanded extracellular space and axonal loss (van Walderveen, Kamphorst et al. 
1998). 
2.2.4 Cerebrosterol (24S-hydroxycholesterol) 
 
Projects about 24s-hydroxycholesterol (cerebrosterol) have been carried out in our 
clinic in close cooperation with Clinical Biochemistry Department (Professor Ingemar 
Björkhem) since late 1990s by Associate Professor Åke Sidén. Research on 
cerebrosterol was later continued by my supervisor Thomas Masterman together with a 
PhD student in the Department of Biochemistry, Valerio Leoni.  It is great honor to be 
part of cerebrosterol history, carry on research on the same topic, reveal more secrets 
about  cerebrosterol, and to try to make  sense of clinical usability.  
Cholesterol in CNS is found in two major pools: The myelin sheaths and plasma 
membranes of astrocytes and  neurons (Snipes G 1998) . Approximately 70% of the 
brain cholesterol is associated with myelin and brain is the most cholesterol rich organ.  
In adult brain cholesterol synthesis rate is low and the half –life of the cholesterol in the 
brain is estimated to be 5 years (Bjorkhem, Lutjohann et al. 1998).  
Currently two mechanisms for removal of excess of cholesterol from the brain are 
known: APOEE-bound cholesterol transport via CSF (1-2 mg/ day) (Pitas, Boyles et al. 
1987) and excretion through BBB (blood brain barrier) of the hydroxylated form of 
cholesterol  – cerebrosterol (6-7 mg/day) (Lutjohann, Breuer et al. 1996; Bjorkhem, 
Lutjohann et al. 1997; Bjorkhem, Lutjohann et al. 1998). Cholesterol is hydroxylated 
by a CYP46 enzyme called 24S-hydroxylase, that is found 90% in brain, and smaller 
amounts in testis (Lund, Guileyardo et al. 1999), eyes, bone marrow and lungs (Leoni 
2009). For more about 24S-hydroxylase protein and coding gene please read the 
following chapter. 
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Both absolute plasma concentration as well as cerebrosterol/cholesterol levels are stable 
during the age period 5-60 years. The higher concentrations in healthy elderly  
individuals in the age group 60-70 yaers compared to younger ones, is an expression of  
brain volume and liver enzymatic capacity ratio differences between the age groups 
(Bretillon, Lutjohann et al. 2000).  
Cerebrosterol in pathological conditions and diseases. In the EAE mouse model it 
was found that cerebrosterol concentration significantly increased already in day 9, 
before clinical symptoms appear and gradually increases up to 193% in day 17 when 
the animals had recovered from symptoms (Teunissen, Floris et al. 2007). It means 
there is no linear correlation between the neurological status severity and cerebrosterol 
concentration variation. 
Absolute plasma levels of cerebrosterol are elevated in early AD and vascular 
dementia compared with healthy controls (Lutjohann, Breuer et al. 1996).  An Italian 
group has revealed that in early stages of AD, levels of cerebrosterol were higher 
compared to healthy controls and vascular dementia patients (Zuliani, Donnorso et al. 
2011). Compared to healthy controls, plasma concentration of cerebrosterol was lower 
in individuals with advanced AD, Guillain-Barré syndrome, brain tumors, ischemic 
stroke and brain death. Intriguingly, plasma concentration in MS was higher compared 
to healthy controls (Bretillon, Siden et al. 2000). In this cohort one of the MS patients 
had three times higher cerebrosterol concentration in plasma compared to other MS 
patients. Here the first hypothesis generating question has been raised: why? What was 
special with that particular MS patient? 
We generated the hypothesis: cerebrosterol might be a marker of inflammatory relapse 
in MS and set out to test the hypothesis. We initiated study I “Plasma cerebrosterol and 
magnetic resonance imaging measures in multiple sclerosis”. We did not find what 
we looked for, but we made other promising findings: borderline significant 
association of logarithmically transformed cerebrosterol/cholesterol ratio with T1 
hypointense lesion volume (T1 lesions--black holes--irreversible tissue damage--sign 
of neurodegeneration) in the RRMS patient group.  
The cerebrosterol/cholesterol ratio is reduced with advancing age in MS (Karrenbauer, 
Leoni et al. 2006) and AD disease progress (Papassotiropoulos, Lutjohann et al. 2000).
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Figure 2. Cerebrosterol (24S-hydroxycholesterol) synthesis pathway in the brain. 
 
 
2.2.5 CYP46A1 
 
The gene CYP46A1 is located on chromosome 14q32.2 and contains 15 exons and 14 
introns. The enzyme CYP46 is very important for brain cholesterol metabolism and 
might play a role in development of AD.  
In normal conditions CYP46A1 mRNA and protein are localized in neurons that are 
metabolically active: pyramidal neurons in cerebral cortex, Purkinje cells of  
cerebellum, thalamus, dentate gyrus and hippocampus, but not in white matter or 
support cells in mouse brain (Lund, Guileyardo et al. 1999).  In human  brain tissue 
immunostaining of CYP46 protein was found throughout the gray matter; accentuated 
staining was observed in neuronal cells of pyramidal shapes and in white matter in 
axon-like fiber structures (Bogdanovic, Bretillon et al. 2001) . It was shown that under 
pathological conditions CYP46 protein can be found in other structures than neurons. 
In the EAE mouse model, immunostaining of Cyp46 has been shown in perivascular 
infiltrates (macrophages) (Teunissen, Floris et al. 2007) and Cyp46 was found to be 
expressed in glia cells in a rat model of brain injury (Smiljanic, Lavrnja et al. 2010).  In 
AD, in post mortem human brain tissue, CYP46 immunostaining was localized to 
microglia (astrocytes) (Bogdanovic, Bretillon et al. 2001). There are no studies on 
CYP46A1 expression or CYP46 protein localization in post mortem human brain tissue 
in MS.   
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In year 2003, Papassotiropoulos with colleagues investigated and found that the 
CYP46A1 SNP rs754203 was associated with AD pathological features:  higher beta-
amyloid peptides and phosphorylated tau in CSF, and higher beta-amyloid load in brain 
tissue.  In addition, CYP46A1 was associated with late onset AD susceptibility both 
alone (OR =2.26; 95% CI 1.41-3.32) and in synergism with APOE ε4 (OR= 9.6; 95% 
CI, 4.9-18.9) (Papassotiropoulos, Streffer et al. 2003). 
The publication of  Papassotiropoulos (Papassotiropoulos, Streffer et al. 2003) gave us 
inspiration to investigate whether  the SNP rs754203 in intron 2  plays the role alone or 
in synergism with  APOE ε4 for MS susceptibility and/or whether it influences 
disability development in MS measured as age at EDSS 6.0.   
Since 2002, when the first publication  addressing the question of CYP46A1 and AD 
risk was published, more than 20 publications approaching the same question with 
contradicting results have appeared, reviewed in (Garcia, Muniz et al. 2009).  So 
today there is no clear consensus whether or not the SNP rs754203 is a risk factor for 
AD. 
Back in 2003-2004, in the beginning of my PhD studies time, my supervisors and I 
were convinced that the CYP46A1 gene SNP rs754203, which is of importance for 
AD risk as well as pathological features, might be of importance for the 
neurodegenerative process in MS.  
 
 
2.2.1 APOE ε4 
 
The APOE gene, situated on chromosome 19q13 is the most important established 
genetic risk factor for sporadic AD (Haines, Bradford et al. 2002).  Exon 4 within 
APOE contains two SNP at codons 112 and 158.  The gene exists in three common 
allelic forms: APOE ε2, ε3, ε4 that engender six  different genotypes ( ε2/ ε2, ε2/ ε3, ε2/ 
ε4, ε3/ ε3, ε3/ ε4, ε4/ ε4) and three corresponding protein isoforms: E2, E3, E4 
(Weisgraber, Rall et al. 1981). There are two minor allelic forms: ε1 and ε5. 
Polypeptides that are 299 amino acids long are distinguished by having different 
combinations of the amino acids: cysteine and arginine at position 112 and 158.  Due to 
amino acid changes the APOE isoforms displays different physical and biochemical 
properties.   
APOE protein function. APOE functions as a major lipid and cholesterol carrier 
protein in the brain and nervous system (Poirier 1994).  Isoforms E1 and E2 decreases 
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the plasma levels of cholesterol and E3 and E4 increases it. E2 and E3 clear β-amyloid 
plaques 20 times more effectively compared with E4. APOE exerts antioxidant 
activities in the following ranking: E2>E3>E4 (reviewed in (Xuan, Zhang et al. 2011)).   
During the last 20 years many studies were published concerning the APOE ε4 effect 
for MS susceptibility and prognosis with conflicting results. In a meta-analysis in year 
2006 (22 studies, 3299 MS cases and 2532 controls), it was found that APOE ε4 does 
not confer risk for MS susceptibility or affect disability progression. Results from a 
pooled analysis of 4048 cases indicate that APOE ε4 status does not distinguish RR 
from PP disease (Burwick, Ramsay et al. 2006). A new meta-analysis published in year 
2011(Xuan, Zhang et al. 2011) from 5472 MS cases and 4727 controls confirms  again 
that there is no association between the APOE ε4 allele and MS susceptibility.  
Due to clear evidence of no effect of this gene to MS susceptibility and prognosis we 
did not look for an APOE ε4 gene effect primarily but only in synergism with another 
gene, important for neurodegeneration-- CYP46A1.  
The following references supports evidence that APOE ε4 exhibits gender-depending 
differential effects and is the reason why we gender-stratified our cohort in paper III:  
- Cognitive decline in males is associated in with APOE ε4 (Savettieri, Messina 
et al. 2004).   
- APOE ε4 carriership confers 49% higher risk of mortality in males in 
community based cohort of healthy elderly individuals at age 75+ (Rosvall, 
Rizzuto et al. 2009). 
 
 
2.2.2 HLA 
 
Through the years of searching for candidate genes, one has been consistently shown to 
be associated with the risk of developing MS: the HLA class II gene HLA-DRB1 .  
(Oksenberg, Barcellos et al. 1999; Sawcer, Hellenthal et al. 2011). 
The MS-associated HLA class II haplotype consists of alleles of four adjacent genes: 
DRB1*15:01, DRB5*01:01, DQA1*01:02, DQB1*06:02. The carriership of this 
haplotype is most common in Scandinavia and more frequent in patient compare to 
controls; association to MS is found in almost all ethnic groups. 
Linkage and association studies has established HLA-DRB1*15:01 as a major risk 
factor for MS (Kantarci and Wingerchuk 2006). About 60% of Nordic MS patients 
carry HLA-DRB1*15:01 and only 30% of healthy controls (Masterman, Ligers et al. 
2000). 
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HLA-DRB1*15:01 is associated with higher disability and severity and extent of spinal 
cord involvement (Qiu, Raven et al. 2011). Carriership of HLA-DRB1*15:01 and 
presence of OCB lower age at attainment of EDSS 6.0. In another study it was found 
that HLA-DRB1*15:01 was associated with worse performance in cognitive tests, 
higher T2 lesion load on MRI and reduction of  NAA on spectroscopy images (Okuda, 
Srinivasan et al. 2009).   
 
 
2.2.3 Peripheral benzodiazepine receptors, markers of 
activated microglia  
 
Microglial cells represent 5% of the total cell population in the brain. Microglia 
represent the resident macrophages in CNS, capable of phagocytosis and antigen 
presentation. During physiological conditions these cells have low expression of 
receptors associated with macrophage function and are called “resting microglia”, 
reviewed in (Venneti, Wiley et al. 2009). Resting microglia in healthy tissue 
continuously change morphology of complex processes, attempting to assess the 
microenvironment, to make contact with other cells and blood vessels. Hence, even in 
the resting state, microglia are neither dormant nor functionally at rest (Nimmerjahn, 
Kirchhoff et al. 2005).Previously, microglia activation was associated only with pro-
inflammatory processes, but during the recent years evidence of microglia’s 
neuroprotective and anti-inflammatory features has accumulated (Venneti, Wiley et al. 
2009). The pro-inflammatory or anti-inflammatory fate of microglia is determined by 
specificity of the current microenvironment composition (Li, Lu et al. 2007). 
 It is important to distinguish the definitions of microglia and macrophages. Microglia 
are myeloid cells located in or derived from CNS cells present at birth and 
macrophages are monocytes from the bone marrow that have been trafficked to CNS 
after birth (spontaneously, or due to inflammation, injury, etc.) (Venneti, Lopresti et al. 
2012).  
Peripheral benzodiazepine receptors (PBR)  are found on non-neuronal cells, activated 
microglia, and in case of disrupted BBB), on  mononuclear-phagocytic cells invading 
from the blood through the disrupted  BBB, reviewed in (Cagnin, Kassiou et al. 2007). 
PBRs are expressed in low levels on the structures without BBB (choroid plexus, 
ependymal cells lining ventricles). PBR are highly expressed in peripheral organs; 
adrenals, kidneys. (Chauveau, Boutin et al. 2008).  
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PBR is also called translocator protein (18 kDa).  The name per se describes the 
function of the protein: binding and transport of cholesterol and proteins into 
mitochondria (Papadopoulos, Baraldi et al. 2006). 
[11C]PK11195 or 1-(2-chlorophenyl-) N-methyl-n-(1-metylpropil)-3-isoquinoline 
carboxamide is a specific ligand of PBR. In MS, [11C]PK11195 binding has been 
identified on activated microglia- macrophages, in areas of focal pathology co-localized 
with T1, T2 weighted MRI lesions, NAWM, and gray matter (Banati, Newcombe et al. 
2000).  The biggest overlap between MRI pathology and [11C]PK11195 binding is co-
localized at the Gd-enhanced lesions area, where 30% of the volume showed 
significantly increased [11C]PK11195 binding. As a tracer of activated microglia PBR, 
[11C]PK11195 has been used in other diseases to visualize activated microglia: 
Rasmussen’s encephalitis, idiopathic Parkinson’s disease, multiple system atrophy, 
progressive supranuclear palsy, AD, stroke, post-herpetic encephalitis, traumatic and 
peripheral nerve injury (Cagnin, Kassiou et al. 2007).   
Vinpocetine (ethyl-apovincaminate), structurally related to the vinca minor alkaloid-
vincamine, is used as a neuroprotective drug in several European countries. 
Distribution of intravenously injected and orally administrated [11C]vinpocetine both in 
monkeys(Gulyas, Halldin et al. 1999) and in humans(Gulyas, Halldin et al. 2002) is 
similar, with the highest uptake in basal ganglia, thalamus and visual cortex. The 
hypothesis that vinpocetine binds to PBR was generated from a study that showed 30% 
less uptake of [11C]-(R)-PK11195 in monkey brains after intravenous pre-treatment 
with 3mg/kg of vinpocetine (Gulyas, Halldin et al. 2005). The vinpocetine molecule 
has highest affinity in vitro to PBR (IC50=0.2 μM) and other receptors like α2β 
adrenoreceptors (IC50=0.9 μM) (Gulyas, Halldin et al. 2002).Despite evidence of some 
unspecificity of vinpocetine binding to PBR, ethical permission was obtained to 
conduct a pilot study in 4 MS patients to compare binding qualities to Gd-enhanced 
lesions and characteristics of the new ligand [11C]vinpocetine  compared to the 
established ligand [11C]PK11195.   
 
Note: IC50 –is the half maximal inhibitory concentration –is a measure of effectiveness 
of an inhibitory compound at a specific concentration to block half of the maximal 
biological effect.  It is a measure used to evaluate potency of an antagonist drug used in 
pharmacological research.  
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2.2.4  OCB 
 
Since the 1940s it is known that 90% of MS patients have increased intrathecal 
production of immunoglobulin in CSF, (reviewed in (Cross and Waubant 2011) .   
OCB are present in 10% of healthy individuals and 95% of Northern European MS 
patients (Andersson, Alvarez-Cermeno et al. 1994), but only 50% of Japanese MS 
patients (Fukazawa, Kikuchi et al. 1998; Kikuchi, Fukazawa et al. 2003) harbor OCB in 
CSF.     
 
 
 
 
Figure 3.The readout of gel electrophoresis of CSF paired with plasma taken on the 
same occasion. On the left side, example with OCB in CSF (the first column) and 
paired plasma sample from the same patient (second column).  Note the differences in 
disposition of lines in the first column, lower segment - these are OCB. The last two 
columns represent electrophoresis of CSF and plasma without OCB.  
 
Definition: presence of one or more oligoclonal IgG bands in CSF detected by 
isoelectric focusing which is absent in plasma (Olsson, Kostulas et al. 1984).  
OCB have a high diagnostic sensitivity (90-100%) and specificity (35%) to detect MS, 
but might be present in CSF due to other reasons of inflammation or due to CNS 
infection. 
OCB are produced by clonally expanded CD138+ plasma cells and plasma blasts (von 
Budingen, Gulati et al. 2010). Older publications state that OCB, once present, persist 
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in the patient´s CSF irrespective of MS course or treatment. There have however been 
recent reports about quantitative (amount of bands) and qualitative (present-absent) 
changes during the course of disease (or treatment).  
In current McDonald’s criteria there are no requirement for presence of OCB as 
diagnostic criteria for RRMS diagnosis. For PPMS diagnosis, presence of OCB is 
included as one of optional requirements. In Nordic MS patients, OCB-positive MS is 
associated with HLA-DRB1*15:01, OCB-negative MS is associated with HLA-
DRB1*04.   
 
 
2.3 OUTCOME MEASURE-EDSS 
 
Expanded disability Status Scale (EDSS) is a measurement of MS caused handicap and 
disease progression which is widely used in randomized clinical trials (RCT) as an 
endpoint measurement for clinical evaluation, despite non –linearity. The scale assesses 
neurological function, walking ability, and self-care functions.  
 
EDSS shortcomings:  
- based on neurological examination that is subjective,  
- the scale has low reliability inter –rater and within-rater ,  
- the scale is used is nonlinear-ordinal scale  where the clinical importance of 1.0 
change depends on starting score,  
- correlates weakly with MRI measures (Sormani, Bonzano et al. 2010)  
- impact of cognitive impairment for total score is low. 
 Despite all shortcomings and in lack of a better scale, the MS society is using EDSS 
both in clinical daily work and as endpoint measurement in RCT.  
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2.4 POPULATION 
 
 
2.4.1 Paper I 
 
This study was conducted in collaboration with the Neurology clinic at Queen square 
Hospital, London. We have obtained clinico-demographical data, MRI lesion volume 
data and plasma samples for 56 MS patients (37RR and 19PP). For 23 controls we have 
received demographical information and plasma samples.  
RRMS was diagnosed according to McDonald’s criteria (McDonald, Compston et al. 
2001), and PPMS was diagnosed according to Thompson’s criteria (Thompson, 
Montalban et al. 2000). 
 
 
2.4.1 Paper II 
 
We examined 4 MS patients, who attended the MS center at Karolinska University 
Hospital Huddinge. Patients were examined with PET scan and MRI at the time point 
of relapse.  
 
 
2.4.2 Paper III 
 
We included 692 well characterized Nordic MS patients, attending the Karolinska 
University Hospital neurology clinic (both Huddinge and Solna sites) and 658 Nordic 
controls (blood donors).  
 
 
2.4.3 Paper IV 
 
Complicated study population and information gathering process I describe below as a 
flowchart. For detailed written description please refer to paper IV. 
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2.5 METHODS 
 
 
2.5.1 Isotope Dilution Mass spectrometry 
 
Detection of cerebrosterol in plasma according the method described previously 
(Dzeletovic, Breuer et al. 1995).  
 
 
2.5.2 Brain imaging. Manual, semi-automated and 
automated lesion assessment. 
 
Brain imaging. In studies I, II and IV patients were examined by 1, 5 T MRT scanner 
either on Siemens, Magnetom (Erlanger, Germany) or GE, Signa (General Electrics 
Medical Systems, Milwaukee, Wis, USA). The PET examination was made at 3D 
acquisition mode on a Siemens ECAT EXACT HR scanner. Patients were examined 
twice the same day: the first examination was performed with intravenously injected 
PET ligand [11C] PK111195 and two hours later with [11C] vinpocetine (paper II).  
 
Lesion assessment methods.  In paper I lesions were outlined by a semi-automated 
method (Sailer, O'Riordan et al. 1999). Lesion volumes were calculated using 
Dispimage software (Plummer 1992).  
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Lesion identification has been done manually: in paper II lesions on MRI were 
identified by two examiners with inter-examiner reproducibility 90% and in paper IV 
lesions were identified by one examiner with single rater variability 93.3%. 
 
 In paper II, on reconstructed PET-images, anatomical regions of interest were drawn 
using the Karolinska Institute’s computerized Human Brain Atlas. PET and MRI were 
co-registered, regional and lesion volumes were calculated by using in-house modified 
version of SPM2 (Statistical Parametrical Mapping).    
  
 
2.5.1 Genotyping 
 
Paper III: Genotyping of  CYP46A1 intron 2 SNP designated rs754203 was performed 
by Pyrosequencing (Ronaghi 2003).  The APOE ε4 codon-112 SNP was analysed by 
TaqMan assay (Applied Biosystems, Foster city, California, USA).  
 
Paper IV: Genotyping of HLA-DRB1*15 and HLA-DRB1*04 has been performed by 
sequence-specific PCR using a commercial kit (Olerup SSP AB, Saltsjöbaden, 
Sweden). 
 
 
2.6 STATISTICS 
 
In paper I, multiple logistic regression analysis was used to calculate the influence of 
MRI measures on cerebrosterol levels using as independent variables, the three 
lesion-volume parameters and the potential confounder age at sampling; and as the 
dependent variable, the cerebrosterol–cholesterol ratio, doubly logarithmically 
transformed to fulfill the assumption of normally distributed residuals. In the same 
paper Scheffe’s post hoc test was used, to compare cerebrosterol–cholesterol ratio 
levels in RRMS patients, PPMS patients and controls.  
 
Odds ratio (OR) is the ratio between the odds of being exposed for the variable in 
patients and in the healthy individuals.  
OR = odds among the patients /odds among the healthy controls 
odds among patients = Ncase( gene carriers)/Ncase(gene non-carriers) 
odds among healthy = Ncontr(gene carriers)/Ncontr(gene non-carriers) 
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OR = 1 means that the odds of exposure among patients are equal to the odds of 
exposure among healthy individuals, i.e. that exposure has no effect on disease 
susceptibility.  A value of more than one indicates risk variable and a value of lower 
than 1 indicates a protective variable. 
 
In paper III, logistic regression analysis has been performed and OR estimates the 
influences of genotypes CYP46 A1AA and APOE ε4 on risk of developing MS. In 
addition relative risk due to interaction (RERI) was calculated . 
  
Cox regression analysis was performed in order to calculate hazard-ratio (HR) which 
estimates the influences of either CYP46 A1AA or APOE ε4or both genotypes on age at 
which patients reach EDSS 6.0 (need of unilateral walking assistance).  HR is a 
measure of how often a particular event (reaching EDSS 6.0) happens in one group 
compared to how often it happens in another group, over time.  Women and men, 
negative for both genotypes were defined as reference with HR estimate = 1. A HR of 
greater than one means that patients were at risk of reaching EDSS 6.0.   
 
 
Survival analysis (Kaplan –Meier) was used in paper III to calculate cumulative 
proportions of patients reaching EDSS 6.0. In paper IV, associations between 
confounders (course, treatment and EDSS) at the time of MRI scanning and 
explanatory variables (OCB and HLA-allele carriage status) were investigated using 
logistic regression analysis. 
 
Proportional ordinal logistic regression analysis was used to calculate OR reflecting 
influences of OCB, HLA-DRB1*15 and HLA-DRB1*04 for T2 lesion load extension 
in MS specific neuroanatomical compartments, total T1 and T2 lesion load (paper 
IV).   
    
  
  
 22 
2.7 RESULTS 
 
2.7.1 Paper I 
 
There was statistically significant lower log transformed cerebrosterol-cholesterol 
concentration in PPMS (n=14; p=2.7 x 10-5) and RRMS (n=20; p=0.0015) compared to 
healthy controls (n=6) in the age group older than 36 years; in the same age group there 
was no statistically significant difference between patients subgroups PPMS and 
RRMS (p=0.465). There was no statistically significant correlation with EDSS in 
neither PPMS (n=19; r= -0.06; p=0.792) nor in RRMS (n=30; r=0.14; p=0.465) 
[Spearman’s correlation coefficient].  
 
Multiple linear logistic analysis revealed a negative correlation between the age at 
sampling and log—log-transformed cerebrosterol-cholesterol ratio values with 
statistical significance in the PPMS group (β= -0.76; p=0.006). The T1 hypo-intense 
lesion volume was correlated positively with ratio values both in PPMS (β=0.064) and 
RRMS (β=0.59); in the latter group the correlation reached borderline statistical 
significance (p=0.052).  For more results details please see original article enclosed in 
the thesis book.  
 
  
2.7.2 Paper II 
 
Volumes of gray, white matter, ventricular and subarachnoid CSF as well as total 
intracranial volume have been measured. Gray matter volume ranged 722-862 ml, 
white matter volume ranged 386-506 ml, ventricular CSF volume ranged 26-30 ml; 
Subarachnoidal CSF ranged from 242-278 ml and intracranial volume ranged 1486-
1639 ml. 
Due to differences of radioactivity per μmol of ligand at the time point of injection it 
was important to calculate the global uptake of radioactivity 2 min after radiolabeled 
ligand injection. Due to 40.4±24.3% more administered radioligand entered brain after 
[11C]vinpocetine injection compared to after [11C] PK111195 injection, 40.7±22.3% 
more radioligand was in the brain 2 min after [11C]vinpocetine injection compared to 2 
min after [11C] PK111195 injection. The total brain uptake of radioactive ligand was 
calculated as a percentage of total injected radiolabeled ligand.  
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In order to show and compare the specificity of radiolabeled ligands to bind to areas 
adjacent to plaques, binding potential (BP) in normal brain parenchyma and BP in 
plaques were compared. Co-registration of MRI and PET images shows evidently the 
differences of binding pattern between [11C]vinpocetine and [11C] PK111195.      
 
 
2.7.3 Paper III 
 
CYP46A1AA and MS risk 
In the overall data set the carriership of CYP46A1AA genotype increased risk for MS 
(OR=1.12), but a 95% confidence interval overlapped unity (0.91-1.39).  
Due to known differential effects of  CYP46A1AA for cholesterol turnover in a knock 
out mouse model and APOE ε4 differential effect for longevity in humans (Rosvall, 
Rizzuto et al. 2009), for further analysis we stratified the cohort by gender. Females, 
carriers of CYP46A1AA alone, carriers of APOE ε4 alone and carriers of both 
genotypes were associated with reduced risk for MS, OR= 0.91; 95% confidence 
interval overlapped unity (0.55-1,51). Males, carriers of both genotypes were associated 
with increased risk for MS, OR=1.51; 95% confidence interval overlapped unity.  
Neither of results reache statistical significance 
 
CYP46A1AA and MS prognosis 
Cox regression analysis was performed in order to calculate HR to reach EDSS 6.0 at a 
specific age, depending on carriership of either CYP46A1AA or APOE ε4 or both. 
Analysis groups were stratified by gender. In females, carriership of either CYP46 A1 
AA or APOE ε4 or both have a protective effect of reaching EDSS 6.0, but 95% HR 
estimate overlapped unity. In males, CYP64A1AA alone and in combination with 
APOE ε4, hastened attainment of  EDSS 6.0. Male carriers of both genotypes attained 
EDSS 6.0 endpoint 17 years earlier compared to male non-carriers (HR=2.04 for 
carriers).  Again 95% confidence interval overlapped unity.  
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2.7.4 Paper IV 
 
 Proportional ordinal logistic regression analysis showed no significant association of 
OCB status, HLA-DRB1*15 or HLA-DRB1*04 carriership and higher lesion load 
adjacent to the lateral ventricles, juxtacortical lesion load, nor with total T2-weighted 
lesion load or the total number of non-contrast-enhanced T1-weighted 
lesions in the brain. A trend was seen for a more than two-fold risk of 
increased lesion burden in the infratentorial compartment in OCB-positive 
patients; similar trends were not seen for HLA-DRB1*15 or 
HLA-DRB1*04 carriage. 
 
 
 
2.8 DISCUSSION 
 
2.8.1.1 Paper I 
This paper was conducted in cooperation with Queen square Hospital, London .The 
data set with information on the T2, T1 and Gd-enhanced lesion volume and dataset 
with blood samples was partially matched, resulting in a total number of 37 RRMS 
patients and 19 PPMS patients with complete datasets.   
The high value of logarithm transformed cerebrosterol - cholesterol ratio in RRMS 
patients in the age group younger than 36 years can be explained with current 
knowledge of cerebrosterol dynamics in neurodegenerative processes over time (or 
increasing individual age). Increased cerebrosterol in normal older individuals is a 
predictor of MCI eight years later.(Hughes, Kuller et al. 2012). We do not have any 
cognitive assessment for the current cohort but I assume that patients, younger than 36 
years in the RRMS group have a slight cognitive impairment (SCI) or are cognitively 
normal and I could speculate that some PPMS patients older than 36 years would fulfill 
the criteria for MCI or dementia. This could be explained by both cholesterol and 
cerebrosterol in CNS being neurotoxic and causing necroptosis in vitro (Yamanaka, 
Saito et al. 2011)of neurons that in its turn causes neurodegeneration. PPMS patients 
are in another pathophysiological process with more pronounced cortical damage and 
atrophy and predominant neurodegeneration and here the logarithmic transformed 
cerebrosterol-cholesterol ratio value is low due to the already reduced amount of 
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metabolically active neurons and reduced bulk volume of myelin. However, the 
subgroup of patients is small and may not represent the general PPMS population.  
 EDSS does not correlate with the cerebrosterol-cholesterol ratio, and the reasons might 
be following:   
1. EDSS is a non- linear measure of disability and handicap.  
2. Processes ongoing in the spinal cord could contribute to changes of cerebrosterol 
concentrations in the plasma as well as to EDSS, but unfortunately this paper lacked 
data on MRI lesion load of the spinal cord. 
3. There is no clear correlation between the  disability  dynamics and cerebrosterol 
concentration fluctuations in the EAE mouse model:  cerebrosterol concentration 
reaches significantly higher levels already days before the development of the first EAE 
clinical symptoms (day 10) and reaches its peak at an approximately 200% increase 
when the animals have recovered and have no clinical EAE signs (day 17 ) (Teunissen, 
Floris et al. 2007). 
4.  EDSS does not correlate with either absolute cerebrosterol levels or cerebrosterol-
cholesterol ratio in our small yet unpublished pilot study of 24 MS patients, who are 
assessed for EDSS and a battery of neurocognitive tests. However, we did find an 
inverse correlation between absolute cholesterol concentration and information 
processing speed. 
5. Cerebrosterol is not a specific marker either for inflammation or in 
neurodegeneration-we do not know which ongoing process in CNS cerebrosterol 
fluctuation in plasma reflects.  
The borderline significance of correlation (p=0.052, β= 0.59) between the T1 
hypointense lesion volume and cerebrosterol-cholesterol ratio in the RR group is worth 
attention. T1 lesions (black holes,-irreversible tisseue damage and axonal loss) and 
could be a marker of neurodegeneration. One must be cautious interpreting statistical 
results with borderline significance and not to over interpret the data. However 
preliminary data in our pilot paper of 24 MS patients support the hypothesis of a 
cerebrosterol correlation with the other measures of neurodegeneration: An absolute 
level of cerebrosterol positively correlates with cortical volume, ventricular CSF and 
brain parenchymal fraction.  
 
On a group level, the logarithm transformed cerebrosterol-cholesterol ratio 
concentration is reduced with increasing age in both MS groups (RR and PP) which 
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reflects reduction of both total brain volume and of number of metabolically active 
neurons as a consequence of accumulated years with tissue damaging disease.      
In conclusion this paper shows that cerebrosterol is a potential biomarker of 
neurodegeneration in MS patients with a predominantly inflammatory process (RR 
group), but the study needs to be repeated in larger sample.  
We wrote in the last sentence in our publication that studies with longer follow up need 
to be conducted and we kept our promise.  We did investigate cerebrosterol levels in 
MS patients in a longitudinal seven year follow up paper.  For more about that paper 
please see chapter “Current status and future prospects”.    
With the retrospective view of our results and publications, now is the time to sum up 
and see what is lacking in order for cerebrosterol to be recognized as a biomarker with 
potential clinical utility. 
Some of the requirements are already fulfilled: 
1. Biologically meaningful. The biomarker is relevant: during the pathological 
process with high membrane turnover the concentration of cerebrosterol both in 
CNS and blood is increased. Cerebrosterol is neurotoxic, causing necroptosis of 
neurons. The total amount of metabolically active neurons will be reduced due 
to both disease progress and the neurotoxic effect of cerebrosterol.  The total 
amount of cholesterol in brain will be reduced by instant leakage of cholesterol 
from the brain. A combined effect of these factors will be a reduced absolute 
concentration of cerebrosterol in the blood.  
2. Clinical relevance. It is evident that reduced amount of cortical neurons (what is 
found in advanced neurodegenerative processes) will lead to worse performance 
in neurocognitive tests. Reduced amount of neurons (reduced cortical volume) 
correlates with reduced total cerebral volume. In early stages of the 
neurodegenerative process cerebrosterol concentration correlates negatively 
with the scores of cognitive tests (high cerebrosterol, - low score). At the 
timepoint of advanced neurodegeneration low performance in neurocognitive 
tests correlate with low cerebrosterol concentrations in plasma (low 
cerebrosterol, low score).  
3. Practical advantages. Cerebrosterol is a stable molecule, found in blood 
(plasma/serum) from easy obtainable body fluids; low amounts of plasma 
/serum are needed in order to analyze by isotope-dilution mass-spectrometry; 
the price of cerebrosterol analysis is comparable to existing routine blood 
sample prices. 
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These criteria still need to be fulfilled:   
1. Confirmed correlation of cerebrosterol levels to other established biomarkers 
(cortical volume, cortical thickness, BPF as well as retinal cortical thickness 
with optical coherence tomography (OCT).  
2. Confirmed correlation between cerebrosterol levels and disability (EDSS and 
SDMT) and prognosis.   
3. Confirmed correlation of cerebrosterol levels with treatment effects.  
 
Studies of large collections of MS patients are required in order to address these issues. 
For planned future studies please see chapter “Current status and future prospects”. 
 
 
2.8.1.2. Paper II 
 
In our pilot study we investigated the difference of two PBR binding patterns in MS 
patients: well-known [11C]-( R)-PK11195 and the new PBR PET marker 
[11C]vinpocetine.  
The prospective advantages of the [11C]vinpocetine as PET ligand are the possibility to 
administer orally and better penetration through the BBB. 
 In the current paper [11C]vinpocetine was administered intravenously.  
[11C]vinpocetine was binding to areas corresponding to T2 lesions on brain MRI but in 
a different pattern compared to [11C]-( R)-PK11195. Why does [11C]vinpocetine but not 
the [11C]-(R)-PK1119 (except in one MS patient) bind to areas corresponding to T2 
hyperintense lesions on MRI? Some of the possible explanations are listed below:   
1. better penetrance of 11C]vinpocetine through the BBB,   
2. [11C]vinpocetine binds to the different PBR subunit compared to [11C]-(R)-
PK1119.  It is hypothesized that a huge molecular complex changes molecular 
conformation and exposes different binding sites depending on stages of glia 
activation. 
3. Affinity of [11C]vinpocetine to  bind to other receptors, not only PBR:  
            sodium and potassium channel receptors, adrenergic α receptors, peripheral  
            GABAA-benzodiazepine receptors, dopamine D4.2 receptors  
            (Gulyas, Halldin et al. 2002).  
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The fact that [11C]vinpocetine uptake is increased in the brain after [11C]-PK11195 
pretreatment (Gulyas, Halldin et al. 2002) makes us question the study design many 
years later.  Have we got false positive results due to microglia activation or BBB 
permeability alteration due to [11C]-PK11195 administration prior to [11C]vinpocetine 
injection? Would it have been better first to inject [11C]vinpocetine and later [11C]-
PK11195 in order to find out the true [11C]vinpocetine binding to MS lesion areas in 
PBR ligand untreated patients?  
I agree with the experts in the field that [11C]vinpocetine needs more research in order 
to map and identify better molecular, cellular and tissue structures to which 
[11C]vinpocetine binds during MS lesion development over time.   
 
 
2.8.1.2 Paper III 
 
In this paper the weakest part is the small amount (9) of individuals of CYP46A1 AA 
and APOEε4 carriers that reach EDSS 6.0 17 years earlier compared to non-carriers.  
So of course the paper needs to be repeated in a bigger sample population.  During my 
half time seminar I, together with my supervisors, have been thinking of repeating the 
study in a larger (hypothesis confirming) sample as a part of this paper. We have 
however made some changes: we chose SDMT as an outcome measure with a new 
paper design and different statistics methods which will result in another kind of paper 
and therefore we decided to make two separate projects.  For project details please see 
chapter “Current status and future prospective”. 
The benign phenotype of female MS patients who are carriers of CYP46A1 AA and 
APOEε4 is not a big surprise. Females and males do have slightly different cholesterol 
metabolism and especially cerebrosterol metabolism differs between males and 
females. In the Cyp46A1-/- knockout mice, male and female phenotypes differed a lot: 
males were slower, had learning difficulties, and performed worse in cognitive tests 
(Kotti, Ramirez et al. 2006); females were active and “over performers” (personal 
communication Ingmar Björkhem). Animal studies concerning Cyp46A1-/- knockout 
phenotype characterization are performed only on male mice.  The APOE ε4 
contribution to a female benign phenotype might be explained by APOE ε4 gender 
specific effect for survival/ longevity: APOE ε4 conferred 49% elevated risk for death 
for males in a community based sample of elderly individuals (Kungsholmens 
prospective cohort, 75+ years old, n=1094) (Rosvall, Rizzuto et al. 2009).     
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I admit that investigating the genes that affect neurodegeneration needs 
neurodeneration specific and sensitive outcome measures. Such measures are: SDMT, 
volumetric measures of brain tissue volumes and fractions. EDSS probably is not the 
optimal outcome measure for neurodegeneration.   
   
 
2.8.1.3 Paper IV 
 
The most important and critical question in this paper is whether the groups (OCB-
negative and OCB-positive) in the paper are comparable due to different factors: group 
differences in treatment frequency and duration and a wide range of age.  
  
 
Never treated 
n (%) 
Ever treated  
n (%) 
Mean duration (months) of 
treatment per patient 
In group Out of all treated 
OCB-negative 20 (50%)    19(47.5%) * 25 **     55.2 *** 
OCB-positive 12(20%) 48(80%) * 39.4 ** 49.2 *** 
 
Two sample T- test, *p = 0.0004, **p =0.58, *** p=0.084 
 
Table. Treatment frequency differences and mean duration in OCB-negative and OCB-
positive patients.   
 
There is a variation in the MRI protocol that  depends on the time point of MRI 
examination: the oldest  MRI examination from year 1999 and from other hospitals 
(Sabbatsberg)  included sequences  of 96  slices;  in year 2001  MRI sequences 
contained 129 slices; the newest protocol used since year 2006 contained  169 slices. 
This means that sensitivity to find T2 lesions is higher on MRI examination according 
to the latest protocol compared to the examinations in year 1999.  A higher number of 
slices, i.e. thinner slices, increase the sensitivity of the examination to find lesions.  
However, this paper might suffer from selection bias affecting the results. Blood 
donation for research is a voluntary act of patients in order to contribute to scientific 
development and research. The more often patients come to the MS center, the higher 
the chance to be requested to donate blood for research. These patients are less 
handicapped, have less fatigue, and less cognitive symptoms.  In the selection of 
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patients, we used patients that were genotyped for HLA and within that group we 
searched patients that had available MRI data from close to their 40th birthday.   
Now when we know the paper outcome and with the retrospective knowledge, I would 
rather choose diagnostic MRI made at the time point close to MS diagnosis so I could 
exclude the effect of covariates such as treatment. On the other hand, I still do not know 
at which age MS patients reach the most pronounced phenotypical diversity of T2 
lesion load in total brain and in specific MS typical compartments.  
This is an explorative, observational paper that did not require specific funding to 
conduct (except brain power work). Information has been used from the already 
available resources of information:  genotyping database, the Swedish MS registry and 
clinical MRI archives. The primary endpoint of this paper is to see whether such studies 
are possible to conduct using retrospective data. The paper is underpowered but is still 
the first and largest paper to investigate the impact of OCB and  HLA-DRB1*04 and 
HLA-DRB1*15 on total lesion load,  T1 hypointense  lesion load,  contrast loading 
lesion load on whole brain MRI and T2 lesion load in MS specific neuroanatomical 
compartments.  This is a pilot paper to assess how we can use our internal, already 
accumulated information resources, to answer questions related to clinical work, using 
tools that do not differ a lot from clinical situations (e.g. a clinical neuroradiologist 
evaluates MRI images). This is not the end of investigations of this cohort; we are 
planning to investigate the effect of OCB carriership and HLA genotypes for brain 
tissue atrophy measures using the automated volumetric method “Free surfer”.  For 
more details on that please see “Current status and future prospects”.   
 
 
 
2.8.2 Current status and future prospectives 
 
2.8.2.1 Paper I 
 
We have already completed the collection of data of longitudinal and cross-sectional 
data for 30 MS patients.  Together with a neuropsychologist at our clinic, Gösta 
Bergendal, and a physicist, Leszek Stawiarz, we collected longitudinal and cross-
sectional data for 30 MS patients; patients were examined with SDMT, at 3 time points: 
1996, 2004 and 2011. Blood samples for cerbrosterol were collected in 2004 and 2011. 
MRI has been done once, in 2004.  We did fulfill our promise to do a follow up project 
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on longitudinal cerebrosterol concentration changes.  Advanced statistics is still 
remaining to be done, but preliminary observations show statistically significant 
correlations between cerebrosterol and MRI images in a cross-sectional sample in 
2004: a positive correlation with volume of ventricular CSF and a negative correlation 
with cortical volume.  In a prospective dataset we saw that high cerebrosterol values in 
2004 are predictors of cognitive impairment in 2011. So in light of these observations, 
cerebrosterol is a potential marker of neurodegeneration in MS.    
Another study to promote cerebrosterol as potential biomarker would be to collect 
evidence about treatment influence for plasma cerebrosterol levels. The first cohort I 
would be eager to use for such a study is the Swedish Tysabri ® cohort (IMSE project). 
In the frame of this project, plasma samples are already collected before Tysabri ® 
treatment start. Plasma is collected repeatedly yearly during Tysabri ® treatment and 
stored in a biobank. The MS registry will serve as a source of clinico-demographic 
information about the patients, included in the study. The disadvantage is that we do 
not have a placebo group.  Deeper thoughts and detailed project design for such a 
study, I will develop after my thesis defence.   
 
The next step for cerebrosterol, to qualify as a clinical biomarker, would be to involve 
cerebrosterol as an outcome biomarker in large multicenter placebo-controlled clinical 
trials. Advantages with such studies are that paper design already has been processed 
by authorities and other responsible persons. The difficult part is to persuade and 
convince primary investigators and responsible persons that cerebrosterol is a marker 
worthy of attention and future studies, and that multicenter trials could with certainty 
answer the question whether treatment affects the levels of cerebrosterol and whether 
there exist any differences of cerebrosterol levels between groups treated with 
immunomodulatory drugs and placebo groups.  
And the final step, many years later, when there is a sufficient amount of positive 
robust studies concerning the cerebrosterol-clinical outcome relationship, will be to 
perform meta-analysis and to reveal mathematical relationships between cerebrosterol 
and clinical outcome.  
 
   
2.8.2.2 Paper II 
 
Currently, I do not plan future studies in the PET-vinpocetine area. 
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2.8.2.3 Paper III 
 
From an immunochip genotyping database (approximately 2000 individuals) we will be 
able to get CYP46A1 SNP rs754203 genotypes and APOE ε4 carriership status.  As an 
outcome measure we will choose z value of SDMT (normalized for age and absolute 
value of SDMT).  We will perform survival analysis. As time axis we will choose age 
at reaching SDMT value 43, an important practical milestone indicating risk for an 
individual to lose his/her driving license or  have impaired employment status ( part-
time or full time sick leave)  in the next 3 years due to reduced cognitive performance.    
     
 
 
2.8.2.4 Paper IV 
 
Currently we are continuing the investigation of structural MRI differences between 
OCB-positive / OCB negative groups. By using the method FreeSurfer (automated 
vertex based morphometry) we will assess the differences in cortical, white matter 
atrophy in defined groups.  With the in house developed software (validated method for 
volumetry of lesion), that uses a multimodal approach for lesion determination, we will 
assess T2, T1 and Gd-enhanced lesion volume differences in the groups.  A future plan 
is also to conduct a prospective study on a hospital based cohort, without selection bias. 
For that study we will include patients prospectively.  At that time we will already have 
power calculation for the FreeSurfer method for volumetric evaluation of gray, white 
substances and CSF in OCB-positive and OCB-negative groups.   
 
2.8.1 Biomarker and outcome measure I would like to use 
in the future: Optical coherence tomography (OCT) 
 
Retinal nerve fiber layer thickness (RNFL) is a non-invasive method, based on 
emission of low coherence infrared light through the pupil and reflection from the 
retina (Huang et al. 1991). The method has advantages: it is non-invasive, not painful 
for the patient, cost and time effective. 
 Retrograde trans-synaptic axonal degeneration (due to lesions along the 
retrochiasmatic visual pathways) is the reason for RNFL thinning. Thickness of RFNL 
shows significant inverse correlation with EDSS (Siger, Dziegielewski et al. 2008) and 
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correlation with MRI atrophy measures (Sepulcre, 2007).   Measurement of RNFL by 
OCT still needs validation in longitudinal studies to find out whether RNFL thickness 
might be used as outcome measure in clinical trials of neuroprotective drugs.    
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